<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
Nov 14, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29th Annual Healthcare Conference at 2:50 p.m. ET on Wednesday, November...
Nov 7, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017. "Third quarter results were in line with our expectations, despite wea...
Nov 1, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating Officer, John Onopchenko. The awards were approved by Endologix's ...
Oct 26, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel 2017 Healthcare Conference at 2:00 ...
Oct 19, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October 30, 2017. Mr. Onopchenko will be responsible for managing ...
Oct 10, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017. The Company's management wi...
Oct 6, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to commence a confirmatory cli...
Sep 21, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix® EndoVascular Aneurysm Sealing System ("Nellix") with the refined Indications for Use (IFU). Nellix is being s...
Sep 11, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. ("JLL") pertaining ...
Aug 17, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD (Looking at Evar Outcomes by Primary Analysis of Randomized Data) clinical study. LEOPARD is the first and onl...
Aug 2, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2017. "While we are pleased with the overall results in the second quarter, the ...
Jul 12, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2017 after the market close on Wednesday, August 2, 2017. The Company's management wi...
Jul 10, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Canaccord Genuity 37th Annual Growth Conference at...
Jun 3, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that prospectively enrolled patients with abdominal aortic aneu...
May 31, 2017
First Prospective Clinical Trial to Evaluate Endovascular Aneurysm Repair (EVAR) in Women IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation...
May 17, 2017
Company to Host an Investor Conference Call on May 18, 2017 at 7:30 a.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administra...
May 4, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017. "We are pleased with our progress during the quarter and our solid start to...
Apr 24, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter's submission "Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes From the EVAS F...
Apr 17, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2017 after the market close on Thursday, May 4, 2017. The Company's management will ...
Apr 4, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"), a leading healthcare investment organization, to provide Endologix with up to $170...
Mar 31, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinica...
Mar 13, 2017
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chairman and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference at 8:35 a.m. ET on Wednesday, March ...
Feb 22, 2017
IRVINE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2016. John McDermott, Endologix Chief Executive Officer, said, "In 2016, we successfully completed the TriVas...
Feb 14, 2017
IRVINE, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study, a multi-center post-mark...
Feb 7, 2017
IRVINE, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday, February 22, 2017 after the close of the market. ...
Feb 6, 2017
John McDermott to Continue as Chief Executive Officer IRVINE, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that its Board of Directors has elected to separate the positions of Chairman of the Board and Chief Executive Officer, ef...
Feb 3, 2017
IRVINE, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob, Chief Financial Officer, is scheduled to present at Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. The Leerink Conference will utiliz...
Jan 25, 2017
IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA Systems has been reinstated, effective immediately....
Jan 25, 2017
IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional Course (LINC Symposium) in Leipzig, Germany.  The...
Jan 17, 2017
IRVINE, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that the company has resumed shipments of all sizes of AFX®2 Endovascular AAA Systems.  The large diameter sizes of AFX2 were placed on a temporary hold December 27, 2016, to i...
Jan 3, 2017
IRVINE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Franc...
Dec 30, 2016
IRVINE, Calif., Dec. 30, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today issued a letter to physicians with updated information about the AFX® Endovascular AAA System. Guidance to PhysiciansThe voluntary letter, issued after discussions with the U.S....
Dec 29, 2016
Schedules Conference Call for December 30, 2016 at 9:00 am ET IRVINE, Calif., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today provided an update on the previously announced temporary hold on shipments of its AFX® and AFX2® Endovascular AA...
Dec 27, 2016
Conference Call Scheduled for 9:00 am ET Today, December 27, 2016 IRVINE, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced a temporary hold on shipments of its AFX® Endovascular AAA System to complete an investigation of a manuf...
Dec 19, 2016
IRVINE, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the Australian Therapeutic Goods Administration (TGA) has approved the AFX®2 Bifurcated Endograft System for inclusion on the Australian Register of Therapeutic Goods. The...
Dec 6, 2016
IRVINE, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will participate at the Guggenheim Securities 4th Annual Boston Healthcare Conference in Boston, MA. This conference will allow institutional investors to meet with the Company b...
Nov 17, 2016
IRVINE, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of two-year clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysm...
Nov 16, 2016
IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 5-year safety and effectiveness clinical data from the global Ovation Pivotal Trial at the 2016 VEITH symposium. The results were presented by Manish Me...
Nov 16, 2016
IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix® EndoVascular Aneu...
Nov 7, 2016
IRVINE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at four investor conferences in November 2016. The first conf...
Nov 1, 2016
IRVINE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2016. John McDermott, Endologix Chairman and Chief Executive Officer, said, "We have now delivered three con...
Oct 25, 2016
IRVINE, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced the appointment of Matthew Thompson, M.D., as Chief Medical Officer effective December 2016. He succeeds David Deaton, M.D., who will continue to work with the Company as a consultant.   ...
Oct 24, 2016
IRVINE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its third quarter 2016 financial results, which will take place on Tuesday, November 1, 2016 after the close of the market, and its 2016 Investor ...
Sep 20, 2016
IRVINE, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Ovation® LIFE (Least Invasive Fast-Track EVAR) study. Zvonimir Krajcer, MD, FACC, Co-Director, Peripheral Vascular Disease Service at Texas Hea...
Sep 6, 2016
IRVINE, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to participate at two investor conferences in September 2016. The first conference is the Morgan Stanley Global Healthcar...
Aug 17, 2016
IRVINE, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the first two patients with abdominal aortic aneurysms ("AAA") have been treated with the Ovation Alto™ Abdominal Stent Graft System. The patients were treated by Andr...
Aug 4, 2016
IRVINE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will present at the 36th Annual Canaccord Genuity Growth Conference in Boston, MA. Event:36th Annual Canaccord Genuity Growth Conference Date: Wednesday, August 10, 2016Time:...
Aug 2, 2016
IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2016. John McDermott, Endologix Chairman and Chief Executive Officer, said, "We continue to deliver solid revenue gr...
Jul 12, 2016
IRVINE, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its second quarter 2016 financial results, which will take place on Tuesday, August 2, 2016 after the close of the market. Endologix will hol...
Jun 9, 2016
IRVINE, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Italian Research Nellix Endoprosthesis ("IRENE") study at the 2016 Society of Vascular Surgery ("SVS") Annual Meeting.  This retrospective, multicent...
Jun 3, 2016
IRVINE, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will present at the Jefferies Healthcare Conference in New York, NY. Event:  Jefferies Healthcare ConferenceDate:  Tuesday, June 7, 2016Time:  10:30 am ETParticipant:  John Mc...
May 26, 2016
IRVINE, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today positive clinical data from the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study (www.clinicaltrials.gov, NCT01726257).  This multicenter, pro...
May 16, 2016
IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LIFE study, a multi-center post-market registry designed to evaluate the Ovation ® Abdominal Stent Graft Platform when used in th...
May 9, 2016
IRVINE, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2016. John McDermott, Endologix Chairman and Chief Executive Officer, said, "In the first quarter we completed our merger ...
Apr 29, 2016
IRVINE, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is ...
Apr 28, 2016
IRVINE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the first data presentation from the ASCEND Registry (Aneurysm Study for Complex AAA: Evaluation of Nellix Durability), a physician-initiated registry of the Nellix® EndoVascu...
Apr 27, 2016
IRVINE, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive clinical data for the Nellix® EndoVascular Aneurysm Sealing System ("Nellix EVAS System") at the 38th Annual Charing Cross Symposium being held Ap...
Apr 19, 2016
IRVINE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its first quarter 2016 financial results, which will take place on Monday, May 9, 2016 after the close of the market. Endologix will hold a co...
Apr 11, 2016
IRVINE, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of CE (Conformite Europeenne) Mark of the next-generation Nellix Endovascular Aneurysm Sealing System ("Nellix EVAS System"). The first procedures with the new Nellix E...
Mar 8, 2016
IRVINE, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first two patients with abdominal aortic aneurysms ("AAAs") in Japan have been treated with the Nellix® EndoVascular Aneurysm Sealing System ("Nellix EVAS System"). T...
Feb 29, 2016
IRVINE, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX®2 Bifurcated Endograft System was performed at Maine Medical Center (MMC), in Portland, ME. The procedure was perfor...
Feb 22, 2016
8% Constant Currency Revenue Growth for the Full Year 2015 2015 Nellix European Systems Increase 42% Over Prior Year Provides 2016 Financial Guidance for Combined Company Following Completion of Merger with TriVascular Technologies, Inc. on February 3, 2016 IRVINE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), d...
Feb 19, 2016
IRVINE, Calif., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in February. The first conference...
Feb 18, 2016
IRVINE, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2015 financial results, which will take place on Monday, February 22, 2016 after the close of the market. En...
Feb 3, 2016
IRVINE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has successfully completed the previously announced merger with TriVascular Technologies, Inc. John McDermott, Chairman and Chief Executive Officer of Endologix, said, ...
Jan 4, 2016
IRVINE, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA.  Event:  34th Annual...
Dec 10, 2015
IRVINE, Calif., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the AFX® Endovascular AAA System for the treatment of abdominal aortic aneurysms has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW)....
Nov 24, 2015
IRVINE, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, Vaseem Mahboob, Chief Financial Officer, and Bob Mitchell, President, are scheduled to participate at two investor conferences in Decembe...
Nov 19, 2015
IRVINE, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of updated clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms (...
Nov 18, 2015
IRVINE, Calif. and SANTA ROSA, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) and TriVascular Technologies, Inc. (Nasdaq:TRIV) today announced that the U.S. Federal Trade Commission and Department of Justice have granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 w...
Nov 18, 2015
IRVINE, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the start of a physician-initiated registry of the Nellix® EndoVascular Aneurysm Sealing System ("Nellix EVAS System") used with aortic branch stent grafts for the treatment of p...
Nov 9, 2015
IRVINE, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, Vaseem Mahboob, Chief Financial Officer, and Bob Mitchell, President, are scheduled to participate at four investor conferences in Novembe...
Nov 4, 2015
IRVINE, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2015 investor meeting, which will be held on November 19, 2015 from 5:30 to 8:00 pm ET at the New York Hilton Midtown. The event will include a Company update, includin...
Oct 28, 2015
IRVINE, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX) ("Endologix" or the "Company") today announced the pricing of its underwritten public offering of $110.0 million aggregate principal amount of its convertible senior notes due 2020 (the "Notes"), which represents a decrease of $40.0 million from the aggregate principal ...
Oct 26, 2015
IRVINE, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") announced today that it intends to offer, subject to market conditions and other factors, $150 million aggregate principal amount of its convertible senior notes due 2020 (the "Notes") in an underwritten offering registered under the Secur...
Oct 26, 2015
Nellix European Systems Increase 45% Over Prior Year FDA Approves Additional Patient Enrollment in Nellix U.S. CAP IRVINE, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ende...
Oct 26, 2015
Combined Product Portfolio to Provide Clinicians With a Broad Range of Endovascular AAA Devices Will Expand U.S. and European Sales Organizations to Enhance Growth and Provide Excellent Clinical Support Endologix to Host Conference Call Today at 5:00 p.m. ET IRVINE, Calif., and SANTA ROSA, Calif., Oct. 26, 2015 (GLOBE NEWSW...
Oct 20, 2015
IRVINE, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its third quarter 2015 financial results, which will take place on Monday, October 26, 2015 after the close of the market. Endologix will ho...
Oct 12, 2015
IRVINE, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for the AFX®2 Bifurcated Endograft System for the treatment of abdominal aortic aneurysms (AAA). This new de...
Sep 17, 2015
IRVINE, Calif., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Vaseem Mahboob to the position of Chief Financial Officer, effective October 15, 2015. Mr. Mahboob succeeds Shelley Thunen, who is resigning as part of the Comp...
Sep 9, 2015
IRVINE, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to participate at two investor conferences in September. The first conference is the Credit Suisse 6th Annual Small & Mid Ca...
Aug 10, 2015
IRVINE, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Bob Mitchell, President, is scheduled to present at the Canaccord Genuity 35th Annual Growth Conference in Boston, MA. Event: Canaccord Genuity 35th...
Aug 3, 2015
IRVINE, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2015. John McDermott, Endologix Chairman and Chief Executive Officer, said, "Sales of Nellix Systems set a new rec...
Jul 9, 2015
IRVINE, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2015 financial results, which will take place on Monday, August 3, 2015 after the close of the market. Endologix w...
Jun 17, 2015
IRVINE, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of 30-day outcomes for the pivotal cohort from the Company-sponsored investigational device exemption (IDE) clinical investigation, the EVAS FORWARD-IDE Study (www.cl...
May 27, 2015
IRVINE, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to present at the Jefferies 2015 Global Healthcare Conference in New York, NY. Event: ...
May 4, 2015
IRVINE, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 40th Annual Health Care Conference in Boston, MA. ...
Apr 29, 2015
IRVINE, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2015. John McDermott, Endologix Chairman and Chief Executive Officer, said, "During the first quarter we continued to d...
Apr 29, 2015
IRVINE, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of updated clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms ...
Apr 29, 2015
IRVINE, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Leslie V. Norwalk, Esq., will be joining the Endologix Board of Directors effective May 1, 2015. Following her appointment, Endologix will have six independent directors and one...
Apr 13, 2015
IRVINE, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2015 financial results, which will take place on Wednesday, April 29, 2015 after the close of the market. Endolog...
Mar 12, 2015
IRVINE, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, has decided to resign from her position in order to spend more time with family and pursue other personal interests. Ms. Thunen will con...
Mar 3, 2015
IRVINE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference in Dana Point, CA. Event: 27th Annu...
Feb 25, 2015
Includes 12% Constant Currency Revenue Growth for the Fourth Quarter and Full Year 2014 Provides 2015 Financial Guidance IRVINE, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve mon...
Jan 26, 2015
IRVINE, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2014 financial results, which will take place on Wednesday, February 25, 2015 after the close of the market...
Jan 5, 2015
IRVINE, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Event: ...
Nov 25, 2014
IRVINE, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at two investor conferences in December. The first conference is the 26th Annual Piper Jaffray Healthcare Conference in New York, N...
Nov 20, 2014
IRVINE, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of initial clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms (...
Nov 18, 2014
IRVINE, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the Company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nel...
Nov 6, 2014
IRVINE, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Company management is scheduled to participate at three investor conferences in November. The first conference is the Stephens 2014 Fall Conference in New York, NY. ...
Nov 3, 2014
IRVINE, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2014 investor meeting, which will be held on November 20, 2014 from 5:00 to 7:30 pm ET at the New York Hilton Midtown. The event will include a Company update, presenta...
Oct 30, 2014
IRVINE, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2014. John McDermott, Endologix Chairman and Chief Executive Officer, said, "Our third quarter revenue was ...
Oct 9, 2014
IRVINE, Calif., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2014 financial results, which will take place on Thursday October 30, 2014 after the close of the market. Endologix...
Sep 29, 2014
IRVINE, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the third quarter ended September 30, 2014. Endologix anticipates third quarter 2014 global revenue of approximately $37.0 million, representing app...
Sep 29, 2014
IRVINE, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the EVAS FORWARD - Global Registry. From October 2013 to September 2014, the registry enrolled 300 patients treated with the Nellix® ...
Sep 29, 2014
LEOPARD Study to Enroll 600 Patients to Provide a "Real-World" Head-to-Head Comparison of the AFX® System Versus Other Commercially Available EVAR Devices IRVINE, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it will c...
Aug 5, 2014
IRVINE, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, is scheduled to present at the Canaccord Genuity 34th Annual Growth Conference in Boston, MA. Ev...
Jul 30, 2014
IRVINE, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2014. John McDermott, Endologix Chairman and Chief Executive Officer, said, "We achieved strong second quarter re...
Jul 16, 2014
IRVINE, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2014 financial results, which will take place on Wednesday, July 30, 2014 after the close of the market. Endologi...
Jun 17, 2014
IRVINE, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has achieved $10 million in trailing twelve month international sales of the Nellix® EndoVascular Aneurysm Sealing System, triggering a milestone payment to the former Ne...
May 28, 2014
IRVINE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference in New York, NY. Event: Jefferies 2014 Glo...
May 2, 2014
IRVINE, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first confer...
Apr 30, 2014
Europe Revenue Growth Exceeds 90% Reiterates 2014 Financial Guidance IRVINE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2014. John McDermott, Endologix Ch...
Apr 21, 2014
IRVINE, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2014 financial results, which will take place on Wednesday, April 30, 2014 after the close of the market. Endolog...
Mar 6, 2014
IRVINE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first co...
Feb 27, 2014
IRVINE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013. John McDermott, Endologix Chairman and Chief Executive Officer, said, "We achieved strong growth in ...
Feb 10, 2014
IRVINE, Calif., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its new VELA™ Proximal Endograft System. The VELA Proximal Endograft is specifically designed for the treatment of proximal aortic neck anatomies dur...
Feb 6, 2014
IRVINE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market. ...
Jan 21, 2014
IRVINE, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix® EndoVascul...
Jan 6, 2014
IRVINE, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 32nd Annual JP Morgan Healthcare Conference in San Francisco, CA. Event:  32nd ...
Dec 20, 2013
IRVINE, Calif., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to begin a pivotal clinical trial to evaluate the sa...
Dec 5, 2013
IRVINE, Calif., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced the pricing of its public offering of $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 1933, as amended. The Company ...
Dec 3, 2013
IRVINE, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced that it intends, subject to market and other conditions, to offer $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 19...
Nov 25, 2013
IRVINE, Calif., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at two investor conferences in December. The first conference is the Piper Jaffray 25th Annual Healthcare Confere...
Nov 12, 2013
IRVINE, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2013 investor meeting, which will be held on November 20, 2013 from 5:30 to 7:00 pm ET at the New York Hilton Midtown. The event will include a Company update, present...
Nov 5, 2013
IRVINE, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at the Stephens Fall Investment Conference in New York. Event: Stephens Fall Investmen...
Oct 30, 2013
IRVINE, Calif., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2013. John McDermott, Endologix President and Chief Executive Officer, said, "We had a strong third quarter...
Oct 14, 2013
IRVINE, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2013 financial results, which will take place on Wednesday, October 30, 2013 after the close of the market. Endolo...
Sep 5, 2013
IRVINE, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate in two upcoming investor conferences in September...
Aug 1, 2013
IRVINE, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference in Boston, MA. Event: ...
Jul 30, 2013
IRVINE, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2013. John McDermott, Endologix President and Chief Executive Officer, said, "Our second quarter revenue was in-l...
Jul 18, 2013
IRVINE, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2013 financial results, which will take place on Tuesday, July 30, 2013 after the close of the market. Endologix ...
Jul 1, 2013
Raises Full Year 2013 Revenue Guidance Conference Call Scheduled for Today, July 1, at 9:00 a.m. ET IRVINE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the second quarter ended June 30...
May 8, 2013
IRVINE, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate in three upcoming investor conferences in May and J...
Apr 30, 2013
Provides Update on New Product Pipeline Including Enhancements to Ventana Program That Will Delay IDE Enrollment and Limited Market Introduction in Europe Reiterates 2013 Financial Guidance IRVINE, Calif., April 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic dis...
Apr 16, 2013
IRVINE, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement for a broadened indication for the Company's 21Fr profile and smaller...
Apr 15, 2013
IRVINE, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Roderick de Greef will retire from the Board of Directors at the end of his current term, which ends on May 23, 2013, the date of the Company's annual shareholder meeting. Thoma...
Apr 8, 2013
IRVINE, Calif., April 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2013 financial results, which will take place on Tuesday, April 30, 2013 after the close of the market. Endologix ...
Mar 11, 2013
IRVINE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer and Shelley Thunen, Chief Financial Officer, are scheduled to present at the 25th Annual ROTH Conference in Laguna Niguel, ...
Feb 27, 2013
IRVINE, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2012. John McDermott, Endologix President and Chief Executive Officer, said, "In 2012 we achieved another ...
Feb 7, 2013
IRVINE, Calif., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2012 financial results, which will take place on Wednesday, February 27, 2013 after the close of the market....
Jan 28, 2013
IRVINE, Calif., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was rec...
Jan 24, 2013
IRVINE, Calif., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms ("AAA"). Nell...
Jan 7, 2013
IRVINE, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2012. Endologix anticipates fourth quarter 2012 global revenue of approximately $29.2 million and ...
Jan 3, 2013
IRVINE, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Event:  31s...
Jan 2, 2013
IRVINE, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Shelley B. Thunen to the position of Chief Financial Officer, effective immediately. Ms. Thunen succeeds Robert J. Krist, who, as previously announced, has decide...
Dec 31, 2012
IRVINE, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that its distribution partner in Japan, Cosmotec Inc., has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the IntuiTrak® Delive...
Dec 31, 2012
IRVINE, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has become aware that Lifeport Sciences, LLC, which is affiliated with Acacia Research Corporation, has filed a lawsuit against Endologix in the United States District Court i...
Dec 4, 2012
IRVINE, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Robert J. Krist, Chief Financial Officer, has decided to retire. Mr. Krist will continue to serve as the Company's Chief Financial Officer until a successor has been hired and wil...
Nov 6, 2012
IRVINE, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to participate in five upcoming investor conferences in November and December. The first conference is the Step...
Oct 25, 2012
IRVINE, Calif., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2012. John McDermott, Endologix President and Chief Executive Officer, said, "During the third quarter we c...
Oct 17, 2012
IRVINE, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2012 financial results, which will take place on Thursday, October 25, 2012 after the close of the market. Endolog...
Oct 17, 2012
IRVINE, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into a comprehensive settlement agreement with Cook Incorporated in the patent infringement lawsuit filed against the Company in October 2009 and which involved tw...
Oct 1, 2012
IRVINE, Calif., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Charles Love to the position Vice President of Clinical Affairs. Mr. Love will be responsible for overseeing all Endologix U.S. and international clinical trials ...
Sep 12, 2012
IRVINE, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to participate in the Lazard Capital Markets Corporate Access Day investor conference in Boston. This confere...
Sep 6, 2012
IRVINE, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the current version of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic ...
Sep 4, 2012
IRVINE, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 2012 Morgan Stanley Global Healthcare Conference in New York. Event: 2012 Morg...
Jul 26, 2012
IRVINE, Calif., July 26, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2012. John McDermott, Endologix President and Chief Executive Officer, said, "We achieved 33% revenue growth for ...
Jul 20, 2012
IRVINE, Calif., July 20, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2012 financial results, which will take place on Thursday, July 26, 2012 after the close of the market. Endologix...
May 30, 2012
IRVINE, Calif., May 30, 2012 (GLOBE NEWSWIRE) -- Endologix (Nasdaq:ELGX) announced today an underwritten public offering of 2,700,000 shares of its common stock. The Company has granted the underwriter a 30-day option to purchase an additional 405,000 shares of common stock from the Company to cover over-allotments, if any. The closing of the offer...
May 9, 2012
IRVINE, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 2012 Bank of America Merrill Lynch Health Care Conference in Las Vegas. Event: 2...
Apr 26, 2012
IRVINE, Calif., April 26, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2012. John McDermott, Endologix President and Chief Executive Officer, said, "During the first quarter we continued to ...
Apr 12, 2012
IRVINE, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2012 financial results, which will take place on Thursday, April 26, 2012 after the close of the market. Endologi...
Mar 28, 2012
IRVINE, Calif., March 28, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that after a highly successful and distinguished 15-year career with the Company, Franklin D. Brown has announced his decision to retire as Chairman of the Board at the end of his cu...
Mar 5, 2012
IRVINE, Calif., March 5, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 24th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. ...
Feb 22, 2012
IRVINE, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative medical devices for the treatment of aortic disorders, today announced financial results for the three and twelve months ended December 31, 2011. John McDermott, Endologix President and Chief Executive Officer, said, "In 201...
Feb 10, 2012
IRVINE, Calif., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2011 financial results, which will take place on Wednesday, February 22, 2012 after the close of the market...
Feb 9, 2012
IRVINE, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the completion of patient enrollment in the Company's prospective, multicenter, randomized clinical trial of a bilateral percutaneous approach to endovascular abdominal aortic aneurysm...
Jan 31, 2012
IRVINE, Calif., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's U.S. clinical trial to evaluate the Ventana™ Fenestrated Stent Graft System for the endovascular repair of juxtarenal a...
Jan 3, 2012
IRVINE, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisc...
Nov 21, 2011
IRVINE, Calif., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences and Bob Krist, Chief Financial Officer, is scheduled to presen...
Nov 8, 2011
IRVINE, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the Stephens Fall In...
Oct 27, 2011
U.S. Revenue Increases by 33% Raises Revenue Guidance to $82 Million to $84 Million IRVINE, Calif., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2011. ...
Oct 18, 2011
IRVINE, Calif., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2011 financial results, which will take place on Thursday, October 27, 2011 after the close of the market. Endolog...
Sep 22, 2011
IRVINE, Calif., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Robert Mitchell, President of Global Strategic Initiatives, is scheduled to present at the Jefferies 2011 Global Healthcare Conference in London. Event: Je...
Sep 6, 2011
IRVINE, Calif., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Robert W. Bai...
Sep 6, 2011
IRVINE, Calif., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") conditional approval from the United States Food and Drug Administration ("FDA") to begin U.S. clinical trials to...
Aug 30, 2011
IRVINE, Calif., Aug. 30, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today the appointment of Ruth Lyons to the position of Vice President of Global Marketing. Ms. Lyons brings more than 25 years of marketing and business development experience in th...
Aug 17, 2011
IRVINE, Calif., Aug. 17, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Judge Tanya Walton Pratt of the United States District Court for the Southern District of Indiana in Indianapolis has issued a Markman ruling in the ongoing patent infringem...
Aug 8, 2011
IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ Endovascular AAA System was performed at Edward Hines, Jr. VA Hospital in Chicago, IL. The procedure was perform...
Aug 3, 2011
IRVINE, Calif., Aug. 3, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the 31st Annual Canacc...
Jul 21, 2011
IRVINE, Calif., July 21, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2011. John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased with our progress during the...
Jul 18, 2011
IRVINE, Calif., and BURLINGTON, Mass., July 18, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, and LeMaitre Vascular, Inc. (Nasdaq: LMAT), provider of peripheral vascular devices and implants, announced today that the companies have entered into an early termination...
Jul 12, 2011
IRVINE, Calif., July 12, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2011 financial results, which will take place on Thursday, July 21, 2011 after the close of the market. Endologix will ho...
Jun 15, 2011
IRVINE, Calif., June 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its next generation product, the AFX™ Endovascular AAA System, for the treatment of abdominal aort...
May 6, 2011
IRVINE, Calif., May 6, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 2011 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV. Event: 2011 Bank of ...
Apr 21, 2011
IRVINE, Calif., April 21, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011. John McDermott, Endologix President and Chief Executive Officer, said, "First quarter revenue grew by 28% year-over-year...
Apr 13, 2011
IRVINE, Calif., April 13, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2011 financial results, which will take place on Thursday, April 21, 2011 after the close of the market. Endologix will hold a confere...
Mar 16, 2011
IRVINE, Calif., March 16, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced the filing of its annual report on Form 10-K and certain revisions to its previously reported unaudited fourth quarter and full year 2010 financial results. Upon finalization of the purch...
Mar 7, 2011
IRVINE, Calif., March 7, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA. Event: ROTH 23rd Annual OC G...
Feb 22, 2011
IRVINE, Calif., Feb. 22, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "We made tremendous progress in all areas...
Feb 15, 2011
IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among 33 pat...
Jan 31, 2011
IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR).  The peer-reviewed article reported initial results fr...
Jan 20, 2011
IRVINE, Calif., Jan. 20, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2010 financial results, which will take place on Tuesday, February 22, 2011 after the close of the market. Endologix wil...
Jan 4, 2011
IRVINE, Calif., Jan. 4, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Event: 29th Annual J.P. Mor...
Dec 20, 2010
IRVINE, Calif., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Guido Neels, Managing Director at Essex Woodlands Health Ventures, has joined the Endologix Board of Directors. Essex Woodlands was the majority shareholder of Nellix Inc, whic...
Dec 13, 2010
IRVINE, Calif., Dec. 13, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc.  Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to add...
Nov 29, 2010
IRVINE, Calif., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the 22nd Annual Piper Ja...
Nov 12, 2010
IRVINE, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that a podium presentation on the Company's Ventana™ fenestrated stent graft will be given at the VEITHsymposium 2010 in New York by Daniel G. Clair, MD, Chairman, Cleveland Clinic ...
Nov 10, 2010
IRVINE, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the Lazard Capital Marke...
Nov 3, 2010
IRVINE, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the Company will host a physician conference call on Thursday, November 11, 2010 at 1:00 p.m. ET / 10:00 a.m. PT. to provide further information on the EVAR technology developed...
Nov 2, 2010
IRVINE, Calif., Nov. 2, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the first clinical implant of the Company's Ventana(TM) fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand. The procedure was performed by Andr...
Oct 27, 2010
IRVINE, Calif., Oct 27, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "Our strong results we...
Oct 27, 2010
IRVINE, Calif., Oct 27, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment...
Oct 25, 2010
IRVINE, Calif., Oct 25, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Oppenheimer 21st Annual Healthcare Conference in New York, NY. Eve...
Oct 18, 2010
IRVINE, Calif., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2010 financial results, which will take place on Wednesday, October 27, 2010 after the close of the market. Endolo...
Oct 18, 2010
IRVINE, Calif., Oct 18, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink(R) System for endovascular repair of abdominal aortic an...
Sep 28, 2010
IRVINE, Calif., Sept 28, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the online publication of a long-term outcome analysis of abdominal aortic aneurysm (AAA) patients from the pivotal, multicenter, prospective clinical trials for the C...
Aug 26, 2010
IRVINE, Calif., Aug 26, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it received CE Mark approval to market its expanded offering of Powerlink(R) stent graft products and PowerFit(TM) Aortic Extensions in the European Union. The Co...
Aug 16, 2010
IRVINE, Calif., Aug 16, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has entered into a development agreement and exclusive license with Evasc Medical Systems Corp., for its balloon expandable stent technology. Evasc is a medical...
Aug 11, 2010
IRVINE, Calif., Aug 11, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's pr...
Jul 29, 2010
IRVINE, Calif., July 29, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its new PowerFit(TM) Aortic Extensions. The PowerFit extensions are designed to provide physi...
Jul 26, 2010
IRVINE, Calif., July 26, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the BMO Ca...
Jul 22, 2010
IRVINE, Calif., July 22, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "During the second quarter ...
Jul 13, 2010
IRVINE, Calif., July 13, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2010 financial results, which will take place on Thursday, July 22, 2010 after the close of the market. Endologi...
Jul 6, 2010
IRVINE, Calif., July 6, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has appointed Todd Abraham to the newly created position of Vice President of Operations. Mr. Abraham will be responsible for managing all of Endologix's day-to...
Jun 10, 2010
IRVINE, Calif., June 10, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink(R) stent graft products. The approval covers 31 new sizes ...
Jun 4, 2010
IRVINE, Calif., June 4, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica H...
Jun 1, 2010
IRVINE, Calif., June 1, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference in New York, NY. ...
May 21, 2010
IRVINE, Calif., May 21, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Thomas C. Wilder has joined the Endologix Board of Directors. Mr. Wilder was elected to the Board during the Company's 2010 Annual Meeting of Stockholders held on ...
Apr 28, 2010
IRVINE, Calif., April 28, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of consolidated results from its prospective, multicenter clinical trials of the Company's Powerlink(R) stent graft for the endovascular repair of abd...
Apr 22, 2010
IRVINE, Calif., April 22, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three months ended March 31, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "Our strong first quarter results...
Apr 15, 2010
IRVINE, Calif., April 15, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2010 financial results, which will take place on Thursday, April 22, 2010 after the close of the market. Endolog...
Apr 14, 2010
IRVINE, Calif., April 14, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular ab...
Feb 24, 2010
IRVINE, Calif., Feb 24, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the ROTH 22nd Annual OC Growth Stock Conference at The Ritz-Carlton Hotel in Lag...
Feb 18, 2010
IRVINE, Calif., Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2009. John McDermott, Endologix President and Chief Executive Officer, said, "The fourth quarter ...
Feb 11, 2010
IRVINE, Calif., Feb 11, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2009 financial results, which will take place on Thursday, February 18, 2010 after the close of the...
Jan 13, 2010
IRVINE, Calif., Jan 13, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the United States Patent and Trademark Office (USPTO) has granted both of Endologix's requests for reexamination of the two patents asserted by Cook, Inc. in the l...
Page:
1
2
...
16
Next Last
 
= add release to Briefcase